

Prescriber Service Form

SUBMIT ONLY REQUESTED DOCUMENTS

for *Erivedge*® (vismodegib) capsule

SOBILIT CITE REQUESTED DOCUMENTS

(vismodegib) capsule			Required field (*)	M-US-00006688(v1.0)	08/20
Step 1 Par	tient Information				
Services Requested	*First name:		*Last name:		
(Check all that apply):	*Date of birth (MM/DD/YY	(Y):/	Gender: □ Male □		
☐ Benefits Investigation/	· ·				
Prior Authorization			*State:		
☐ Refer Patient to Co-pay Assistance	-		ell phone: () -		
☐ Appeals Support			anguage: □ English □ Spanish		
	urance Information		gaager 🗖 Engherr 🗖 epanieri		
<u> </u>	Yes No				
			to e u ce	II (000) 044 2224 f	
	d, please complete the Gener			all (888) 941-3331 for assist	ance.
	out the information below or				
Is prior authorization i	•				
	Primary Insuran	<u>:e</u>	Secondary Insurance	Pharmacy Benefit	
Insurance name					
Subscriber name (if not par	tient)				
Subscriber/Policy ID #					
Group #					
Insurance phone					
Step 3	agnosis and Clinical Informa	tion			
To the highest level of spe	ecificity, provide:	Has patient starte	ed therapy? ☐ Yes ☐ No		
		•	al cell carcinoma? ☐ Yes ☐ No		
		*Locally advance	ed basal cell carcinoma recurre	d following surgery,	
Erivedge® (vismodegib) ca	psule 150 mg	or not a candid	ate for surgery, and not a cand	lidate for radiation? \square Yes	□ No
☐ 150 mg daily ☐ Othe		mo	nth supply Refill	times	
Pharmacy and Shipping In	formation:				
	□ No Preferred specialty pha				
	☐ No Onsite pharmacy:				
Ship to: ☐ Patient ☐ Prac	ctice				
Step 4 Pre	escriber Information				
*First name:		*L;	ast name:		
*Practice name:					
		Sui	te: *City:		
	*ZIP:		escriber tax ID #:		
Prescriber NPI [†] #:	•	Gr	oup NPI [†] #:	<i>r</i> /	
Office contact:	Contact	phone: \	Contact	fax: ()	
Step 5 He	alth Care Provider Certifica	tion			
	certify: (a) The above therapy i				
the prescribing physician. (b) If the indication for which thi	s Genentech prod	luct is being prescribed to trea	t is not listed in the FDA-app	roved
label, the prescriber is pres	scribing the medication for an " edication for such a use. (c) The	unapproved" use,	meaning that the FDA has not	approved the efficacy, dosag	ge
	ormation (as defined by the Hea				
Inc., Genentech Access So	utions, the contracted dispensi	ng pharmacy, or c	other contractors for the purpo	se of requesting reimbursem	ent
	ng or continuing therapy, as a k				
hehalf of the nations may in	ll not attempt to seek reimbursenclude benefits investigation (B	ment for free pro	ion (PA) and appeals support (e) The services requested on	tance
foundation referral. In the	absence of a checkbox selecting	g a service, Gener	tech Access Solutions will perf	orm BI/PA services on behalf	
patient. (f) No action on the	nese services will be taken unt	il the patient cor	sent document has been rece	eived.	
Sign data & fav	to				
Sign, date & fax (877) 313-2659	*Prescriber's Signat	ure:		*Date://	
(8//) 3 13-2039		(Original or	stamped signature required)		

†National Provider Identifier.

Erivedge and the Access Solutions logo are registered trademarks of Genentech, Inc.

© 2020 Genentech USA, Inc. So. San Francisco, CA All rights reserved.